Abstracts tagged "interferons and systemic sclerosis"

Abstract Number: 1727 • 2017 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Analysis in Systemic Sclerosis Reveals Hypomethylation of Interferon-Associated Genes in CD4+ and CD8+ T Cells
Weilin Pu¹, Weifeng Ding², Lei Wang³, Shuai Jiang⁴, Wenzhen Tu³, Shicheng Guo⁵, Qingmei Liu⁶, Yanyun Ma⁴, Sidi Chen⁷, Wenyu Wu⁶, Xiaodong Zhou⁸, Maureen D. Mayes⁹, Shervin Assassi⁹, John D. Reveille⁹, Li Jin¹⁰ and Jiucun Wang¹⁰, ¹State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences,, State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai, China, Shanghai, China, ²Medical Laboratory Center, Medical Laboratory Center, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China, Nantong, China, ³Division of Rheumatology, Division of Rheumatology, Shanghai TCM-integrated Hospital, Shanghai, China, Shanghai, China, ⁴Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China, Shanghai, China, ⁵Department of Bioengineering, Department of Bioengineering, University of California at San Diego, CA, USA, San Diego, CA, ⁶Department of Dermatology, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China, ⁷State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences and Institutes of Biomedical Sciences,, State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai, China, Shanghai, China, ⁸Internal Medicine-Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹University of Texas McGovern Medical School, Houston, TX, ¹⁰State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences and Institutes of Biomedical Sciences, State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai, China, Shanghai, China
Background/Purpose: Systemic sclerosis (SSc) is a complex systemic autoimmune disease caused by complicated interaction between genetic, epigenetic and environmental risk factors. Evidence showed epigenetic modifications,…
Abstract Number: 2927 • 2017 ACR/ARHP Annual Meeting
Interferon Regulatory Factor (IRF) 7 in Type I IFN Signaling Represents As a Key Upstream Regulator in Early Diffuse SSc Patients and Plays Critical Role in Pathogenesis of Fibrosis
Minghua Wu¹, Gloria Salazar¹, Jun Ying¹, Julio Charles², Xiaodong Zhou³, Maureen D. Mayes² and Shervin Assassi², ¹Department of Internal Medicine - Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²University of Texas McGovern Medical School, Houston, TX, ³Internal Medicine-Rheumatology, University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Previous global gene expression studies of SSc patients revealed presence of a prominent type I interferon (IFN) signature. IRF7 is a key transcription factor…
Abstract Number: 2902 • 2013 ACR/ARHP Annual Meeting
Key Roles For Interferon and Macrophage Activation In Progressive Lung Fibrosis Associated With Systemic Sclerosis
Romy Christmann¹, Giuseppina Stifano², Claudia Borges³, Carlos Carvalho⁴, Ronaldo Kairalla⁴, Edwin R. Parra⁵, Avrum Spira⁶, Robert W. Simms¹, Percival Sampaio-Barros⁷, Vera L. Capelozzi⁵ and Robert Lafyatis¹, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University Medical Center, Boston, MA, ³Rheumatology, CEUMA University, Sao Luis do Maranhao, Brazil, ⁴Pulmonology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, ⁵Pathology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, ⁶Computational Biomedicine, Boston University School of Medicine, Boston, MA, ⁷Rheumatology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
Background/Purpose: Interstitial lung disease associate with Systemic Sclerosis(SSc-ILD) is one of the leading causes of mortality. We analyzed the gene expression of lung tissue in…
Abstract Number: 2914 • 2013 ACR/ARHP Annual Meeting
Serum Proteins and Whole Blood Transcripts Suppressed By An Anti-Type I Interferon Receptor Monoclonal Antibody In Subjects With Systemic Sclerosis
Xiang Guo¹, Brandon W. Higgs², Christopher Kane³, Chris, A. Morehouse², Zheng Liu², Liangwei Wang⁴, Stephen Yoo⁵, Yihong Yao², Lorin Roskos⁶ and Wendy White⁷, ¹Translational Sciences, MedImmune LLC, Gaithersburg, MD, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ³MedImmune, LLC, Gaithersburg, MD, ⁴Biostatistics, MedImmune, LLC, Gaithersburg, MD, ⁵Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁶One MedImmune Way, Medimmune, Gaithersburg, MD, ⁷Translational Sciences, MedImmune, Gaithersburg, MD
Background/Purpose: To identify serum markers that are modulated by an investigational human IgG1κ monoclonal antibody directed against subunit 1 of the type I interferon receptor…
Abstract Number: 2290 • 2012 ACR/ARHP Annual Meeting
Type I Interferon Associated Gene IRF7 in the Pathogenesis of Fibrosis in Systemic Sclerosis (SSc)
Minghua Wu¹, Michael R. Blackburn², Shervin Assassi¹, Xiaochun Liu¹, John D. Reveille¹, Filemon K. Tan¹, Sandeep K. Agarwal³ and Maureen D. Mayes¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Biochemistry and Molecular Biology, The University of Texas Medical School at Houston, Houston, TX, ³Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX
Background/Purpose: Fibrosis in Systemic Sclerosis is characterized by excessive collagen production and accumulation in the skin and lungs. It has been increasingly appreciated that a…
Abstract Number: 2301 • 2012 ACR/ARHP Annual Meeting
The Interferon Type I Signature Is Increased in Monocytes From Systemic Sclerosis Patients
Zana Brkic¹, Lenny van Bon², Cornelia G. van Helden-Meeuwsen³, Madelon C. Vonk⁴, Hanneke Knaapen⁵, Wim van den Berg⁵, Paul L. Van Daele³, Virgil A. Dalm¹, Timothy Radstake² and Marjan A. Versnel¹, ¹Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht/Radboud University Nijmegen Medical Center, Utrecht/Nijmegen, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁵Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: Systemic sclerosis (SSc) is a complex fibrosing disease of unknown etiology. The past decade clear indications for an aberrant immune system have been revealed.…
Abstract Number: 1474 • 2012 ACR/ARHP Annual Meeting
Interferon-Inducible Chemokines Correlate with Disease Severity in Systemic Sclerosis
Xiaochun Liu¹, Maureen D. Mayes¹, Filemon K. Tan¹, Minghua Wu¹, John D. Reveille², Brock E. Harper³, Hilda T. Draeger⁴, Emilio B. Gonzalez⁵ and Shervin Assassi⁶, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ³Int Med/Rheumatology, University of Texas Medical Branch, Galveston, TX, ⁴Med/Clinical/Immunology, Univ of TX Health Sci Ctr, San Antonio, TX, ⁵Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁶Rheumatology, Univ of Texas Health Science Houston, Houston, TX
Plasma Interferon Inducible Chemokine Score: Stable Marker of Disease Severity in Systemic SclerosisABSTRACT:Background/Purpose: The most prominent gene expression profile in the peripheral blood of patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].